ArticleFrontiers in pharmacology2024
Cost-effectiveness of durvalumab plus tremelimumab in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer from the US healthcare sector's and societal perspectives.
Yena Gan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.